Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
about
Vascular endothelial growth factor inhibitors: investigational therapies for the treatment of psoriasisVEGF inhibition and renal thrombotic microangiopathyAmbulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatmentMelatonin and Other Tryptophan Metabolites Produced by Yeasts: Implications in Cardiovascular and Neurodegenerative DiseasesEfficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled TrialsTargeting angiogenesis in gynecologic cancersAccuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysisCan knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy?Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiologyMedical management of brain tumors and the sequelae of treatment.Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?New approaches for managing preeclampsia: clues from clinical and basic researchTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaPractical management of bevacizumab-related toxicities in glioblastomaDrug-induced glomerular disease: direct cellular injury.Hypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaAngiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysisA humanized anti-VEGF rabbit monoclonal antibody inhibits angiogenesis and blocks tumor growth in xenograft modelsConsidering renal risk while managing cancer.Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Angiogenic inhibition in high-grade gliomas: past, present and future.Thrombospondin 1 and vasoactive agents indirectly alter tumor blood flow.Computational modelling of anti-angiogenic therapies based on multiparametric molecular imaging dataDrug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data.Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.ADAMTS13 Endopeptidase Protects against Vascular Endothelial Growth Factor Inhibitor-Induced Thrombotic Microangiopathy.Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysisAntiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models.Molecular mechanisms of diabetic vascular complicationsClinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis.A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.Bevacizumab increases risk for severe proteinuria in cancer patients.Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia
P2860
Q22305863-A0ED31F5-B675-4CA2-B6FC-259C502BBC1FQ24632792-924B01DC-5F44-4BF9-83A2-45546B4EF0ABQ24657761-E240C59D-28BF-401B-866D-63B1857CDBCBQ26772733-C41C411E-7D6F-4F31-9298-A550806E8BFDQ26786618-D2558A20-87C9-40F0-B024-8F4EA1DD3699Q26824766-AFC6EAEB-7905-42C3-A26D-C304F8D659E3Q26825271-605C4AA5-7D73-46E3-9C33-E9278039724FQ26859144-D222B7D0-8FBD-4EED-8D55-F7DDC9266D68Q26865332-36E30F1E-8741-43B0-AFD7-6EBA0F14DA51Q26992174-F15B2345-2DD2-4D44-A03D-9FDFCF1CDBCFQ27002538-09F5EDDA-A240-4B91-96D4-C0D4AAE4B04FQ27010670-BF45990D-1AB2-4BC3-9681-4084CB39F658Q27013665-D1B69794-BE16-4B15-9E83-84FCB6B48137Q27015852-C437A4F7-2475-4C20-A94D-EFB284407F63Q27692666-31F620F8-33C2-4018-BF47-E5579242BA71Q28066747-DD2B0A9C-A3D8-45F5-8D79-826336508AD6Q28534015-2682E11A-C664-486B-97A0-0DBA51DAF4AFQ28749085-C75D22C4-C3B0-4CAE-ABD6-BCF5C7FBB064Q30234338-B446AF61-4DA3-4687-B35E-C99F279BAA83Q30243969-B7730CCA-0BC3-43A1-A07C-823A0EC07ABEQ30277177-9CE7E63B-6213-417F-80F7-5FD5052D20CDQ30417015-2ED08B4D-9FF8-45A4-9B2A-F9BA696BBBE4Q30455596-2E5E8824-0ABC-49FB-B003-D40B4FE9C0C3Q30482804-A81DF30F-5A64-442A-AFEA-7A3F4D0C7E77Q30564565-01CED517-2951-4A76-A193-C76C89CE18CBQ30616602-30BE5284-5FD1-41D9-A6AA-A526AEFF39F0Q31102468-647597B7-4931-4F32-BC38-29D742AB69B3Q33392652-8108B0A0-9AA4-435F-BC68-5A5D7D9B3BA5Q33414769-8A1BE822-BA85-482E-8ED9-288BC9E425CCQ33423350-65B8CE4A-822E-49E3-ADAA-42316E19A4CFQ33433315-7CAE92F0-0C84-4785-BE59-F3756CBA8CB3Q33558337-B063F46F-2285-431C-A266-41683AE48BACQ33558421-9E7284A9-E05F-4044-87E8-05843B3240E7Q33710753-B16064BB-7700-407F-885B-66B93DD54719Q33893093-0D1F9244-D753-48EF-BFAF-34A635E0CAFAQ33904867-E6BCBF80-3E90-4F48-8992-8420BF05510DQ34063604-B94D20D8-506C-4D7E-A227-767516516B54Q34107482-28245C5A-9B86-4211-80A2-8C2EFB9DD323Q34124173-0F121E55-7CF7-44FC-BAD1-FE60705B3B70Q34140082-1D6697D3-CCE3-4F11-8471-03936C6C34EE
P2860
Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Risks of proteinuria and hyper ...... atic review and meta-analysis.
@ast
Risks of proteinuria and hyper ...... atic review and meta-analysis.
@en
type
label
Risks of proteinuria and hyper ...... atic review and meta-analysis.
@ast
Risks of proteinuria and hyper ...... atic review and meta-analysis.
@en
prefLabel
Risks of proteinuria and hyper ...... atic review and meta-analysis.
@ast
Risks of proteinuria and hyper ...... atic review and meta-analysis.
@en
P2093
P921
P1476
Risks of proteinuria and hyper ...... atic review and meta-analysis.
@en
P2093
Chirag R Parikh
Shenhong Wu
William L Dahut
Xiaolei Zhu
P304
P356
10.1053/J.AJKD.2006.11.039
P577
2007-02-01T00:00:00Z